Literature DB >> 17384366

Serotonin syndrome.

Charlotte Elizabeth Evans1, Joseph Sebastian.   

Abstract

Serotonin syndrome is an under-reported and under-recognised condition that occurs on administration of selective serotonin re-uptake inhibitors alone, or in combination with other medication known to increase levels of 5-hydroxytryptamine. This case report demonstrates signs and symptoms associated with their overdose and illustrates the importance of recognition of this syndrome to instigate appropriate treatment for the patient.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17384366      PMCID: PMC2658256          DOI: 10.1136/emj.2006.040550

Source DB:  PubMed          Journal:  Emerg Med J        ISSN: 1472-0205            Impact factor:   2.740


  5 in total

1.  Serotonin syndrome treated with chlorpromazine.

Authors:  P K Gillman
Journal:  J Clin Psychopharmacol       Date:  1997-04       Impact factor: 3.153

Review 2.  Serotonin syndrome: a brief review.

Authors:  Philippe Birmes; Dominique Coppin; Laurent Schmitt; Dominique Lauque
Journal:  CMAJ       Date:  2003-05-27       Impact factor: 8.262

Review 3.  Serotonin syndrome. Presentation of 2 cases and review of the literature.

Authors:  P J Mason; V A Morris; T J Balcezak
Journal:  Medicine (Baltimore)       Date:  2000-07       Impact factor: 1.889

Review 4.  Serotonin syndrome. A clinical update.

Authors:  K C Mills
Journal:  Crit Care Clin       Date:  1997-10       Impact factor: 3.598

5.  Treatment of the serotonin syndrome with cyproheptadine.

Authors:  A Graudins; A Stearman; B Chan
Journal:  J Emerg Med       Date:  1998 Jul-Aug       Impact factor: 1.484

  5 in total
  4 in total

1.  The FDA alert on serotonin syndrome with combined use of SSRIs or SNRIs and Triptans: an analysis of the 29 case reports.

Authors:  Randolph W Evans
Journal:  MedGenMed       Date:  2007-09-05

Review 2.  Dopamine D3 and 5-HT1B receptor dysregulation as a result of psychostimulant intake and forced abstinence: Implications for medications development.

Authors:  Janet L Neisewander; Timothy H C Cheung; Nathan S Pentkowski
Journal:  Neuropharmacology       Date:  2013-08-23       Impact factor: 5.250

3.  Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species.

Authors:  Adam L Halberstadt; Muhammad Chatha; Adam K Klein; Jason Wallach; Simon D Brandt
Journal:  Neuropharmacology       Date:  2020-01-07       Impact factor: 5.273

4.  Chlordiazepoxide preventive effect on tramadol overdose induced serotonin syndrome evaluated by hunter and radomski criteria: a clinical trial.

Authors:  Seyed Mostafa Mansouripour; Reza Afshari
Journal:  Toxicol Int       Date:  2013-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.